|Eligible Active Ingredient:
||Topical Erythromycin. As a topical preparation not exceeding 4%
|With Effective From:
||Treatment of acne vulgaris
|Maximum Daily Dose:
||Apply to the affected areas twice daily
|Maximum Supply per Transaction:
||30g for gel;30ml for topical solution/lotion
|Minimum Age of User:
|Patient Information Leaflet from HSA/PSS:
||Download PIL (Link to HSA website)
Mechanism of Action of Topical Erythromycin
Erythromycin acts by penetrating the bacterial cell membrane and reversibly binding to the 50 S subunit of bacterial ribosomes or near the “P” or donor site so that binding of tRNA (transfer RNA) to the donor site is blocked. Translocation of peptides from the “A” or acceptor site to the “P” or donor site is prevented, and subsequent protein synthesis is inhibited. Erythromycin is effective only against actively dividing organisms. The exact mechanism by which erythmromycin reduces lesions of acne vulgaris is not fully known: however, the effect appears to be due in part to the antibacterial activity of the drug.
Additional Information of Topical Erythromycin
||Anti-Acne Preparations For Topical Use
||Antiinfectives For Treatment Of Acne
||3”-O-demethylerythromycin | Abomacetin | Eritromicina | Erythromycin A | Erythromycin C | √©rythromycine | Erythromycinum
Show All HSA-registered therapeutic products granted exemption to supply without prescription
- Health Science Authority of Singapore – Reclassified POM
HSA-Registered Products Containing Topical Erythromycin As a topical preparation not exceeding 4%
wpDataTable with provided ID not found!
This list is not exhaustive. HSA collaborates with Pharmaceurical Society of Singapore (PSS) to review the appropriate use of therapeutic products in the community from time to time. Hence, HSA may enable the supply of a Prescription Only Medicine (POM) by pharmacists without a prescription, upon review that the product can be used in a safe and effective manner under the supervision of a pharmacist. This can be effected through legislative mechanisms in the absence of an application made by the product registrant to reclassify the therapeutic product, subject to to conditions including indication, strength, maximum daily dose, maximum supply quantity, and age restriction.